Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sutro Biopharma (STRO) Restructuring Costs (2025)

Sutro Biopharma (STRO) has disclosed Restructuring Costs for 1 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • Quarterly Restructuring Costs changed N/A to $1.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.1 million through Dec 2025, changed N/A year-over-year, with the annual reading at $26.1 million for FY2025, N/A changed from the prior year.
  • Restructuring Costs hit $1.6 million in Q4 2025 for Sutro Biopharma, down from $7.3 million in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $13.0 million in Q2 2025 to a low of $1.6 million in Q4 2025.